![Bertrand Le Conte de Poly](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Aktive Positionen von Bertrand Le Conte de Poly
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Aquyre Biosciences, Inc.
![]() Aquyre Biosciences, Inc. Medical/Nursing ServicesHealth Services Aquyre Biosciences, Inc. is a biotech company that created Celtivity™, a rapid digital specimen adequacy assessment tool that can identify the presence of cancer cells and immune cells in a biopsy in just two minutes. The company is based in Weston, MA and was founded by Bertrand Le Conte de Poly, Claude Boccara. The assessment is presented as a cellular heatmap, making analysis and detection of cancer, granuloma, and immune cells such as lymphocytes relatively easier than traditional cancer diagnostic methods. Floyd Samuel Eberts has been the CEO of the company since 2023. | Direktor/Vorstandsmitglied | - | - |
Technik-/Wissenschafts-/F&E-Leiter | 03.05.2023 | - | |
Gründer | - | - | |
Vorstandsvorsitzender | - | 03.05.2023 | |
Corporate Officer/Principal | 03.05.2023 | - |
Karriereverlauf von Bertrand Le Conte de Poly
Statistik
International
Vereinigte Staaten | 2 |
Operativ
Director/Board Member | 1 |
Chief Executive Officer | 1 |
Chief Tech/Sci/R&D Officer | 1 |
Sektoral
Health Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 1 |
---|---|
Aquyre Biosciences, Inc.
![]() Aquyre Biosciences, Inc. Medical/Nursing ServicesHealth Services Aquyre Biosciences, Inc. is a biotech company that created Celtivity™, a rapid digital specimen adequacy assessment tool that can identify the presence of cancer cells and immune cells in a biopsy in just two minutes. The company is based in Weston, MA and was founded by Bertrand Le Conte de Poly, Claude Boccara. The assessment is presented as a cellular heatmap, making analysis and detection of cancer, granuloma, and immune cells such as lymphocytes relatively easier than traditional cancer diagnostic methods. Floyd Samuel Eberts has been the CEO of the company since 2023. | Health Services |